Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076863 | 0.87 | CSF1R (0.48) | HDAC1HDAC2HDAC3CSF1RACMSD | |
| SCHEMBL5650393 | 0.85 | CSF1R (0.46) | HDAC1HDAC2HDAC3CSF1R | |
| SCHEMBL3092798 | 0.83 | CSF1R (0.41) | HDAC1HDAC2HDAC3CSF1RNPC1 | |
| SCHEMBL20817282 | 0.80 | KDM4E (0.48) | HDAC1HDAC2HDAC3NPC1MAPT | |
| SCHEMBL11863709 | 0.79 | NPC1 (0.42) | CSF1RNPC1MAPTRAB9AACMSD | |
| SCHEMBL5649368 | 0.77 | CSF1R (0.43) | PRKCICSF1RNPC1MAPTRAB9A | |
| SCHEMBL13097768 | 0.77 | RAB9A (0.44) | NPC1MAPTRAB9A | |
| Acetic Acid SCHEMBL5651428 | 0.77 | CSF1R (0.40) | HDAC1HDAC2HDAC3CSF1RACMSD | |
| SCHEMBL11816684 | 0.76 | ACMSD (0.51) | HDAC1HDAC2HDAC3MAPTRAB9A | |
| SCHEMBL5655868 | 0.75 | CSF1R (0.54) | HDAC1HDAC2HDAC3CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | claimed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | claimed |
| US-20160122334-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-05 | — | — | US | disclosed |
| US-9266866-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-23 | — | — | US | disclosed |
| EP-2016074-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| US-20140200245-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-17 | — | — | US | disclosed |
| US-8722718-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-13 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| EP-2016074-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007124321-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249685-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200245-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | HDAC1 1847/4885HDAC2 2650/4885HDAC3 1689/4885 |
| US-20160122334-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | HDAC1 1847/4885HDAC2 2650/4885HDAC3 1689/4885 |
| US-20070249685-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, CAMK4 | HDAC1 809/4885HDAC2 886/4885HDAC3 905/4885 |
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | HDAC1 3806/4885HDAC2 3662/4885HDAC3 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.